An insight on ophthalmic drug delivery systems: focus on polymeric biomaterials-based carriers
Abstract
Presently, different types of eye diseases, such as glaucoma, myopia, infection, and dry eyes are treated with topical eye drops. However, due to ocular surface barriers, eye drops require multiple administrations, which may cause several risks, thereby necessitating additional strategies. Some of the key characteristics of an ideal ocular drug delivery system are as follows: (a) good penetration into cornea, (b) high drug retention in the ocular tissues, (c) targetability to the desired regions of the eye, and (d) good bioavailability. It is worthy to note that the corneal epithelial tight junctions hinder the permeation of therapeutics through the cornea. Therefore, it is necessary to design nanocarriers that can overcome these barriers and enhance drug penetration into the inner parts of the eye. Moreover, intelligent multifunctional nanocarriers can be designed to include cavities, which may help encapsulate sufficient amount of the drug. In addition, nanocarriers can be modified with the targeting moieties. Different types of nanocarriers have been developed for ocular drug delivery applications, including emulsions, liposomes, micelles, and nanoparticles. However, these formulations may be rapidly cleared from the eye. The therapeutic use of the nanoparticles (NPs) is also hindered by the non-specific adsorption of proteins on NPs, which may limit their interaction with the cellular moieties or other targeted biological factors. Functional drug delivery systems (DDS), which can offer targeted ocular drug delivery while avoiding the non-specific protein adsorption could exhibit great potential. This could be further realized by the on-demand DDS, which can respond to the stimuli in a spatio-temporal fashion. The cell-mediated DDS offer another valuable platform for ophthalmological drug delivery.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Glaucoma encompasses a spectrum of neurodegenerative disorders featured by deformation of RGCs and irreversible damage to the optic nerve.
“Glaucoma encompasses a spectrum of neurodegenerative disorders featured by the deformation of RGCs and irreversible damages to the optic nerve [115].”
From From design to Deployment: The innovative role of nanomicelles in targeted ophthalmic therapeutics (2025) · cites this paper as [115]
The citation lists haven’t been fetched yet
References 141 · Cited by 67
- Authors
- Shafiq, M., Rafique, M., Cui, Y., Pan, L., Do, C.-W., & Ho, E. A.
- Affiliations
- Kyushu University (JP)
- Nankai University (CN)
- Hong Kong Polytechnic University (HK)
- University of Waterloo (CA)
- Corresponding author
- Ho, Emmanuel A.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 362
- Pages
- 446-467
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4386272196
- Cited by
- 67
- References
- 141
- Citations by year
- 2026: 21 · 2025: 27 · 2024: 18 · 2023: 1
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Controlled Release (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- ocular drug delivery, polymeric biomaterials, nanocarriers, corneal permeation, protein adsorption, targeted drug delivery, stimuli-responsive drug delivery, cell-mediated drug delivery, liposomes, micelles, nanoparticles, emulsions, eye drops, ocular surface barrier
- MeSH terms
- Animals, Biocompatible Materials, Cornea, Drug Carriers, Eye Diseases, Humans, Ophthalmic Solutions, Polymers, Drug Delivery Systems, Nanoparticles, Administration, Ophthalmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review